Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.95 | N/A | +16.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.95 | N/A | +16.96% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about the company's direction. They noted advancements in their pipeline but acknowledged the need for continued focus.
Management highlighted progress in ongoing clinical trials.
They emphasized a commitment to innovation despite current challenges.
This earnings report shows that Soleno Therapeutics managed to beat expectations on EPS, which is a positive sign for investors. The stock reacted positively, rising by 1.29% in response to the news. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALANTIR TECHNOLOGIE Class A
May 5, 2025